Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cerevel Therapeutics Hldg Inc
(NQ:
CERE
)
44.96
UNCHANGED
Last Price
Updated: 4:15 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
44.96
Bid (Size)
44.97 (20)
Ask (Size)
44.98 (146)
Prev. Close
44.96
Today's Range
44.96 - 44.96
52wk Range
19.59 - 44.96
Shares Outstanding
8,830,700
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CERE Investors Have the Opportunity to Join Investigation of Cerevel Therapeutics Holdings, Inc. with the Schall Law Firm
June 18, 2024
From
The Schall Law Firm
Via
Business Wire
CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) Buyout and Encourages Investors to Contact the Firm
June 11, 2024
From
Kaskela Law LLC
Via
Business Wire
Performance
YTD
+6.52%
+6.52%
1 Month
+1.24%
+1.24%
3 Month
+10.14%
+10.14%
6 Month
+9.07%
+9.07%
1 Year
+91.32%
+91.32%
More News
Read More
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
June 05, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
June 04, 2024
Via
Benzinga
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
May 29, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
May 20, 2024
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
CERE Stock Earnings: Cerevel Therapeutics Hldg Misses EPS for Q2 2024
May 09, 2024
Via
InvestorPlace
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
April 18, 2024
Via
Benzinga
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
April 15, 2024
Via
Investor's Business Daily
Tuesday Talk: Big-Tech Under Attack
March 26, 2024
Via
Talk Markets
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
March 25, 2024
Via
Benzinga
3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024
March 09, 2024
Via
InvestorPlace
Is AbbVie Stock a Buy Now?
February 22, 2024
Via
The Motley Fool
This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
February 16, 2024
Via
Benzinga
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
February 06, 2024
Via
Benzinga
AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall
February 02, 2024
Via
Benzinga
AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures
January 29, 2024
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –
January 29, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
ABBV: This Top Biotech Just Went On A Buying Spree
January 25, 2024
Via
Talk Markets
7 Dividend Aristocrats That Will Pay You for Years to Come
January 22, 2024
Via
InvestorPlace
CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders
January 08, 2024
From
Halper Sadeh LLC
Via
Business Wire
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
Via
Benzinga
Is AbbVie Stock a Buy Now?
January 07, 2024
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.
January 04, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.